DM
UTHR icon

Delphi Management’s United Therapeutics UTHR Stock Holding History

Delphi Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,907
Closed -$1.36M – 91
2024
Q1 		$1.36M Buy
+5,907
New +$1.33M 1.05% 65

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Delphi Management's UTHR Position: Q2 2024 in Review

Delphi Management sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 5,907 shares — an estimated $1.36M sold.

Delphi Management first reported a position in UTHR in Q1 2024 and held it in 1 quarter. The position peaked at $1.36M in Q1 2024. 566 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

  • Delphi Management reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Delphi Management sold 5,907 United Therapeutics shares in Q2 2024, an estimated $1.36M.
  • Delphi Management first reported a position in United Therapeutics in Q1 2024 and held it in 1 quarter.
  • Delphi Management's United Therapeutics position peaked at $1.36M in Q1 2024.
  • 566 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Delphi Management's 13F filing for Q2 2024, filed 26 Aug 2024.